Elsevier

Joint Bone Spine

Volume 72, Issue 6, December 2005, Pages 456-460
Joint Bone Spine

Clinical State-of-the-Art
The RATIO observatory: French registry of opportunistic infections, severe bacterial infections, and lymphomas complicating anti-TnFα therapy

https://doi.org/10.1016/j.jbspin.2005.10.004Get rights and content

Abstract

The RATIO observatory collects nationwide data on opportunistic infections, severe bacterial infections, and lymphomas in patients with a past or present history of tumor necrosis factor alpha (TNFα) antagonist treatment in France. The cases are validated by a committee of experts, and the capture–recapture method is used to check and to improve case ascertainment. A nested case–control comparison is carried out to identify risk factors for the events of interest. The registry differs from other biological registries in that the inclusion criterion is occurrence of the event (infection or lymphoma) instead of administration of the treatment. This method ensures collection of a far larger number of cases. The RATIO observatory is a remarkable example of a three-way partnership of learned societies, pharmaceutical companies, and institutions (the French research institute INSERM and the French drug safety agency AFSSAPS). Over 100 events were reported in the first 16 months, a large increase compared to European registries of fixed patient cohorts monitored for 4–5 years. This result validates our original approach, which will probably need to be extended to other biotherapies for inflammatory joint disease and to other potential adverse events. The strong commitment of rheumatologists in France, who are the main prescribers of TNFα antagonists, and of the French Society for Rheumatology explain the high case-ascertainment and must continue to ensure that answers are rapidly provided to the drug safety questions that are vital to our patients.

Introduction

Tumor necrosis factor alpha (TNFα) is involved in the pathogenesis of chronic inflammatory diseases [1], [2], [3], [4], [5], [6]. TNFα antagonists, which are either antibodies against TNFα or soluble receptors for TNFα, are effective in rheumatoid arthritis [7], Crohn's disease [8], ankylosing spondylitis [9], and psoriasis [10] and have radically improved the prognosis of these conditions in patients who are unresponsive to conventional treatments. TNFα is crucial to defense mechanisms against infections, most notably those caused by intracellular organisms [11]. It induces the differentiation of monocytes to macrophages and plays a key role both in initiating granuloma formation and in maintaining granuloma integrity [12], [13]. Because TNFα antagonists are potent inhibitors of macrophage functions [14], they increase the risk of infection, particularly due to intracellular organisms [15].

Because the risk of infection was predictable, infection rates were monitored carefully during the clinical development of TNFα antagonists. As early as the late 1990s, an increase in cases of tuberculosis was detected in patients taking infliximab. A study of 70 cases reported in the US before June 2000 was published in 2001 [16]. Median time from treatment initiation to the diagnosis of tuberculosis was only 12 weeks, and 40% of patients had extrapulmonary disease (miliary or involvement of the lymph nodes, pleural cavity, or peritoneal cavity). Over 98% of the patients were from areas of low tuberculosis endemicity. These characteristics are consistent with reactivation of quiescent mycobacteria within macrophages. Inhibition of the macrophage response by TNFα antagonist therapy may allow mycobacteria to resume proliferation. The high rate of extrapulmonary disease may reflect an inability to generate a granuloma that walls in the initial focus of pulmonary reactivation.

Recommendations for patients who are starting TNFα antagonist therapy have been developed in several countries. In France, specific tuberculosis prophylaxis guidelines were issued by the RATIO study group [17] and the AFSSAPS. The immune deficiency induced by TNFα antagonists may explain occurrences of other opportunistic infections, and more specifically those caused by intracellular bacteria (e.g. listeriosis) [18], fungi (e.g. histoplasmosis [19], aspergillosis [20], and pneumocystosis [21]), and viruses (e.g. CMV [22]). These infections are often severe and in some cases require intensive care unit admission. Fatal cases have been reported. Finally, TNFα is involved in cytotoxic T-cell responses against lymphomatous B cells [23], [24]. This indicates a theoretical risk of lymphoma in patients taking TNFα antagonists [25], [26], [27]. Studies have shown a small increase in the risk of lymphoma but have failed to determine whether this result is due to the medication or to greater disease activity in patients selected to TNFα antagonist therapy [28].

In this fast-flowing situation, creating a specific system to capture cases of infection and lymphoma in patients on TNFα antagonists was essential. A multidisciplinary task force was set up in France in 2001. Members were representatives of learned societies concerned with TNFα antagonists (rheumatology, gastroenterology, dermatology, infectiology, internal medicine, methodology, and pulmonology). The task force, called research on TNFα antagonists and opportunistic infections (RATIO) has produced most of the studies conducted in France on the safety of TNFα antagonists. The RATIO observatory is a nationwide prospective registry of infections and lymphomas in patients with a past or present history of TNFα antagonist therapy. It pursues a dual objective: to describe infections and lymphomas in patients treated with TNFα antagonists via active surveillance designed to achieve a high case-ascertainment rate and to identify risk factors by conducting a nested case–control study. The RATIO observatory is a clinical research network created by the French societies for rheumatology, gastroenterology, internal medicine, infectious diseases, pulmonology, and dermatology; as well as by pharmacovigilance centers. The observatory efforts are coordinated by two methodologists (Ph. Ravaud and F. Tubach), supported by two publicly funded institutions (the INSERM and the AFSSAPS), and funded in large part by the three pharmaceutical companies that market TNFα antagonists (Abbott, Schering Plough, and Wyeth (Table 1)).

Section snippets

The RATIO observatory

To obtain information on the incidence, natural history, and outcomes of opportunistic infections, severe bacterial infections, and lymphomas in patients with a past or present history of TNFα antagonist therapy, cases are recorded prospectively and monitored for 3 years. Case-ascertainment is the main challenge. Ideally, all cases in France should be identified. To achieve this goal, considerable efforts must be made to motivate clinicians. A letter signed by the AFSSAPS and the RATIO task

The nested case–control study

A nested case–control study is under way to identify risk factors for opportunistic infection, severe bacterial infection, and lymphoma in patients treated with TNFα antagonists. Opportunistic infection, severe bacterial infection, and lymphoma will be analyzed separately.

Conclusion

The objective of the RATIO observatory is to describe infections and lymphomas in patients with a past or present history of TNFα antagonist therapy and to identify risk factors for these events. Available safety data on TNFα antagonists come mainly from three sources: follow-up of patients included in clinical studies (randomized trials and cohort studies), follow-up of patients in everyday practice (most notably via registries such as those maintained in Sweden and in the United Kingdom), and

References (30)

  • P.E. Lipsky et al.

    Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-tumor Necrosis factor trial in rheumatoid arthritis with Concomitant Therapy Study Group

    N. Engl. J. Med.

    (2000)
  • J.D. Gorman et al.

    Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha

    N. Engl. J. Med.

    (2002)
  • C.L. Leonardi et al.

    Etanercept as monotherapy in patients with psoriasis

    N. Engl. J. Med.

    (2003)
  • P. Mastroeni et al.

    Effect of anti-tumor necrosis factor alpha antibodies on histopathology of primary Salmonella infections

    Infect. Immun.

    (1995)
  • K.L. Hyrich et al.

    Anti-tumour necrosis factor alpha therapy in rheumatoid arthritis: an update on safety

    Ann. Rheum. Dis.

    (2004)
  • Cited by (0)

    Lecture held on the occasion of the 18th French Congress for Rheumatology.

    View full text